|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 1110813-31-4 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
Fields of Application :
PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.
| CAS Number: | 1110813-31-4 |
| Purity: | >99% |
| Molecular Weight: | 469.94 |
| Molecular Formula: | C24H25ClFN5O2 |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | PF299804, Dacomitinib, PF-00299804 |
| Chemical Name: | (E)-N-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
Dacomitinib is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). For the detailed information about the solubility of PF-299804 (Dacomitinib, PF-00299804) in water, the solubility of PF-299804 (Dacomitinib, PF-00299804) in DMSO, the solubility of PF-299804 (Dacomitinib, PF-00299804) in PBS buffer, the animal experiment（test） of PF-299804 (Dacomitinib, PF-00299804),the in vivo,in vitro and clinical trial test of PF-299804 (Dacomitinib, PF-00299804),the cell experiment（test） of PF-299804 (Dacomitinib, PF-00299804),the IC50, EC50 and Affinity of PF-299804 (Dacomitinib, PF-00299804) .
References:
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
